Literature DB >> 18637412

Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies.

Jens H Kuhn1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18637412

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN： 0939-1983


× No keyword cloud information.
  113 in total

1.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

Review 2.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

3.  Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.

Authors:  Kevin B Spurgers; Tim Alefantis; Brian D Peyser; Gordon T Ruthel; Alison A Bergeron; Julie A Costantino; Sven Enterlein; Krishna P Kota; R C Dutch Boltz; M Javad Aman; Vito G Delvecchio; Sina Bavari
Journal:  Mol Cell Proteomics       Date:  2010-08-11       Impact factor: 5.911

4.  Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations.

Authors:  Jens H Kuhn; Stephan Becker; Hideki Ebihara; Thomas W Geisbert; Karl M Johnson; Yoshihiro Kawaoka; W Ian Lipkin; Ana I Negredo; Sergey V Netesov; Stuart T Nichol; Gustavo Palacios; Clarence J Peters; Antonio Tenorio; Viktor E Volchkov; Peter B Jahrling
Journal:  Arch Virol       Date:  2010-10-30       Impact factor: 2.574

Review 5.  Conformational plasticity of the Ebola virus matrix protein.

Authors:  Jens Radzimanowski; Gregory Effantin; Winfried Weissenhorn
Journal:  Protein Sci       Date:  2014-09-04       Impact factor: 6.725

6.  Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

Authors:  Andrea Marzi; Heinz Feldmann; Thomas W Geisbert; Darryl Falzarano
Journal:  J Bioterror Biodef       Date:  2011-09-25

7.  Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process.

Authors:  Loreen L Lofts; Jay B Wells; Sina Bavari; Kelly L Warfield
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

8.  A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Authors:  Anthony C Wong; Rohini G Sandesara; Nirupama Mulherkar; Sean P Whelan; Kartik Chandran
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

9.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Authors:  Igor Opsenica; James C Burnett; Rick Gussio; Dejan Opsenica; Nina Todorović; Charlotte A Lanteri; Richard J Sciotti; Montip Gettayacamin; Nicoletta Basilico; Donatella Taramelli; Jonathan E Nuss; Laura Wanner; Rekha G Panchal; Bogdan A Solaja; Sina Bavari
Journal:  J Med Chem       Date:  2011-01-25       Impact factor: 7.446

10.  The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding.

Authors:  Derek Dube; Matthew B Brecher; Sue E Delos; Sean C Rose; Edward W Park; Kathryn L Schornberg; Jens H Kuhn; Judith M White
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.